Medical News Observer

TKey Points:

• HepaFatSmart uses advanced AI to detect liver regions in MRI scans and calculate liver fat fractions (VLFF and PDFF) without user input, reducing the potential for human error.
• Classified as a Class II device, it meets FDA requirements for medical use in diagnosing and managing liver-related conditions. It is specifically useful for patients with fatty liver disease and potential liver donors.
• The software’s effectiveness relies on high-quality MRI images. Healthcare professionals must validate results despite its high repeatability and slight improvements over its predecessor, HepaFat-Scan.

Device Information

HepaFatSmart (V2.0.0) is a software as a medical device (SaMD) designed to automatically analyze magnetic resonance imaging (MRI) datasets for the quantitative assessment of liver fat. The software utilizes a convolutional neural network (CNN) to detect liver regions of interest and calculates the volumetric liver fat fraction (VLFF) and proton density fat fraction (PDFF). HepaFatSmart requires no user input during analysis, minimizing human error​.

Manufacturer Information

Resonance Health Analysis Services Pty Ltd, based in Burswood, Western Australia, developed and is marketing this device. The company specializes in non-invasive medical imaging applications, focusing on liver health diagnostics.

Regulatory Approval Information

The Food and Drug Administration (FDA) has cleared the device under the 510(k) premarket notification process. Under 21 CFR 892.1000, it is classified as a Class II magnetic resonance diagnostic device.

Indications

HepaFatSmart is indicated to support clinical diagnoses in individuals with confirmed or suspected fatty liver disease. It aids in clinical decision-making for managing fatty liver-related diseases or metabolic syndromes and is useful in assessing living donors for liver transplants.

Contraindications

HepaFatSmart cannot be used if MRI is contraindicated or if images do not meet specific quality requirements set by the software protocols.

Study Results

HepaFatSmart was evaluated in several studies, including repeatability and validation studies, demonstrating high repeatability and reproducibility of results. The software performs comparably to its predicate device, HepaFat-Scan, with slight improvements in accuracy and repeatability.

Limitations

The effectiveness of HepaFatSmart depends on the quality of the input MRI images and adherence to the specified imaging protocols. Automated software analysis requires validation by trained healthcare professionals to ensure accuracy in diverse clinical scenarios.

Conclusion

HepaFatSmart has proven to be a reliable tool for quantitatively analyzing liver fat content using MRI. The FDA’s clearance affirms its equivalence to earlier devices like HepaFat-Scan, providing a robust option for diagnosing and managing liver conditions.

Future Implications

As advancements in AI and imaging technology continue, HepaFatSmart may see further enhancements in accuracy, usability, and applicability to other conditions. Ongoing studies and feedback from clinical use will guide these developments, potentially expanding its indications and improving patient outcomes in liver health management.

References

• “Hepafatsmart K231459 510(k) Premarket Notification.”  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K231459.
• Resonance Health.”  https://www.resonancehealth.com/.